Matthew Weston

Stock Analyst at UBS

(2.22)

# 2,798

Out of 4,969 analysts

4

Total ratings

100%

Success rate

7.22%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General

Stocks Rated by Matthew Weston

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	NVO Novo Nordisk	Downgrades: Neutral	n/a	$56.74	-	1	Aug 5, 2025
	NVS Novartis AG	Downgrades: Neutral	n/a	$128.23	-	1	Feb 13, 2025
	AZN AstraZeneca	Upgrades: Buy	n/a	$82.11	-	2	Feb 13, 2025

Novo Nordisk

Aug 5, 2025

Downgrades: Neutral

Price Target: n/a

Current: $56.74

Upside: -

Novartis AG

Feb 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $128.23

Upside: -

AstraZeneca

Feb 13, 2025

Upgrades: Buy

Price Target: n/a

Current: $82.11

Upside: -